Vertex Pharmaceuticals shares are trading higher after the company, along with CRISPR Therapeutics, announced positive, interim data from the investigational CRISPR/Cas9 gene-editing therapy CTX001 in ongoing Phase 1/2 clinical trials.
Benzinga Newsdesk